item management s discussion and analysis of financial condition and results of operations 
as described in item business introduction  the company completed the divestiture of its institutional pharmacies business on december  the company s consolidated financial statements for the fiscal year ended june  report separately the results of operations and net assets of the institutional pharmacies business as discontinued operations 
the following table sets forth for the periods indicated the percentage which certain items in the financial statements of the company bear to net sales 
percentages of net sales fiscal years ended june  net sales costs and expenses cost of sales selling  general and administrative investment income interest expense purchased research and development and other income loss before provision for income taxes 
provision for income taxes income loss from continuing operations the historical operations of the company are primarily related to its plastics technology business 
all revenues and a significant majority of operating expenses were derived from these operations 
as discussed below  the consolidated financial statements for the fiscal year ended june  include certain costs associated with the company s activities in developing its healthcare communications business 
fiscal years ended june  and consolidated results of operations net sales for the year ended june  increased by  or  over the comparable prior year period 
the sales increase was due primarily to increased unit sales in surgical products in the healthcare segment and increased unit sales of writing components  pipette filters and pipette tips in the consumer segment 
cost of sales for the year ended june  increased by  or  over the comparable prior year period due to the increased sales volume noted above and product development costs 
as a percent of net sales  cost of sales for the year ended june  decreased to from in the comparable prior year period principally due to increased leverage of certain fixed costs which do not increase proportionally with sales and improvements in material and labor usage 
selling  general and administrative expenses for the year ended june  increased by  or  over the comparable prior year period due primarily to the inclusion of expenses of  associated with the company s healthcare communications business which primarily related to research and development activities 
excluding these costs  as a percent of net sales  selling  general and administrative expenses for the year ended june  decreased to from due principally to increased sales which were not proportionately offset by such expenses  since a portion of these costs is fixed in nature and does not vary directly with sales 
investment income  which is comprised of interest and other income and dividend income  for the year ended june  increased by  or  over the comparable prior year period primarily as a result of the income earned on the proceeds of the company s  convertible subordinated debentures due the convertible debentures issued in february interest expense for the year ended june  increased by  from the prior year period as a result of the interest expense associated with the company s convertible debentures 
during the year ended june   the company recorded non recurring charges to income of  related to purchased research and development costs from the acquisitions of avicenna and careagents and the acquisition of rights to certain intellectual property and software technologies to be utilized in the development of the company s healthcare communications business 
excluding the portion of the research and development charge relating to the acquisitions of avicenna and careagents for which no tax benefits were recognized  the effective tax rate for the year ended june  increased to from in the prior year period primarily as a result of the change in composition of the company s marketable securities resulting in the decrease in investment income subject to the dividend received deduction 
fiscal years ended june  and consolidated results of operations net sales for the year ended june  increased by  or  over the comparable prior year period 
the sales increase was due primarily to increased unit sales in medical products and plastic vials in the healthcare segment and  to a lesser extent  to increased unit sales of writing components  personal care items and home water filters in the consumer segment 
cost of sales for the year ended june  increased by  or  over the comparable prior year period due to the increased sales volume noted above and additional depreciation and product development costs 
as a percent of net sales  cost of sales for the year ended june  decreased to from in the comparable prior year period principally due to certain fixed costs which do not increase proportionally with sales and improvements in material and labor usage 
selling  general and administrative expenses for the year ended june  increased by  or  over the comparable prior year period due primarily to an increase in expenses associated with the increase in sales volume noted above and an increase in corporate overhead expense 
as a percent of net sales  selling  general and administrative expenses for the year ended june  increased to from in the prior year primarily due to the increased corporate overhead noted above 
interest and other income and dividend income for the year ended june  increased by  or  over the comparable prior year period primarily as a result of the income earned on a full year of investment of the net proceeds received from the sale of the institutional pharmacies business 
interest expense for the year ended june  decreased by  from the prior year period as a result of the conversion and redemption of the company s convertible subordinated debentures due december  the debentures into common stock of the company in february other expenses for the year ended june  decreased by  over the comparable prior year period as a result of the one time charge in december related to the issuance of stock options to certain officers as compensation for services in conjunction with the consummation of the purchase and sale agreement and costs associated with the conversion and redemption in february of the debentures 
the effective tax rate for the year ended june  decreased to from in the prior year period primarily due to the nondeductibility of certain conversion and redemption costs in the prior year 
capital resources and liquidity cash  cash equivalents and marketable securities increased by  to  during the year ended june  principally due to the proceeds from the issuance in february of the convertible debentures 
as a result of the continuing efforts in developing its healthcare communications business  the company expects to incur significant research and development expenditures in connection with this new area of business until the products and services are successfully developed and marketed 
during the second half of the fiscal year ended june   the company incurred expenditures of approximately  related to the development of its healthcare communications business 
the company expects to increase the rate of such expenditures during fiscal the company believes that its cash flow from operations and the income earned on its investments are sufficient to meet the anticipated working capital requirements of its business  including the research and development expenditures noted above 
the company continues to pursue an acquisition program pursuant to which it seeks to effect one or more acquisitions or other similar business combinations with businesses it believes have significant growth potential 
financing for such acquisitions may come from several sources  including  without limitation  a the company s cash  cash equivalents and marketable securities and b proceeds from the incurrence of additional indebtedness or the issuance of common stock  preferred stock  convertible debt or other securities 
there can be no assurance that the company s acquisition program will be successful 
see item business acquisition program 

